Akebia Therapeutics, Inc. (AKBA)
$0.00+$0.00 (+0.16%) TodayExtended Hours
Latest AKBA Insider Trades
Erik Ostrowski - OfficerOpen-market sale
Erik Ostrowski - Officer
John P. Butler - Officer
Steven Keith Burke - OfficerSteven Keith Burke - OfficerAkebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 56,019 | $62K |
| Grant or award | 12 | 535,800 | |
| Option exercise | 2 | 700,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Jun 10, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John P. Butler - Officer | Option exercise | Common Stock | 350,000 | $0.63 | $221K | |
| John P. Butler - Officer | Option exercise | Stock Option (Right to buy) | 350,000 | $0.00 | - | |
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 56,019 | $1.11 | $62K | |
 Myles Wolf | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Myles Wolf | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Cynthia Smith | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Cynthia Smith | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Ron Frieson | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Ron Frieson | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Adrian Adams | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Adrian Adams | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Philip J. Vickers | Grant or award | Stock Option (Right to buy) | 214,400 | $0.00 | - | |
| John P. Butler - Officer | Open-market purchase | Common Stock | 69,270 | $1.25 | $87K | |
| Richard C. Malabre - Officer | Open-market sale | Common Stock | 36,142 | $1.39 | $50K | |
| Richard C. Malabre - Officer | Open-market sale | Common Stock | 13,382 | $1.39 | $19K | |
| Nicholas Grund - Officer | Open-market sale | Common Stock | 53,585 | $1.39 | $74K | |
| Nicholas Grund - Officer | Open-market sale | Common Stock | 31,244 | $1.39 | $43K | |
| Steven Keith Burke - Officer | Open-market sale | Common Stock | 21,582 | $1.39 | $30K | |
| Steven Keith Burke - Officer | Open-market sale | Common Stock | 25,375 | $1.39 | $35K | |
| Steven Keith Burke - Officer | Open-market sale | Common Stock | 20,701 | $1.39 | $29K | |
 Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 16,846 | $1.39 | $23K | |
| Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 25,382 | $1.39 | $35K | |
| Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 27,544 | $1.39 | $38K | |
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 34,951 | $1.39 | $49K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 46,660 | $1.39 | $65K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 96,065 | $1.39 | $134K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 114,891 | $1.39 | $160K | |
| John P. Butler - Officer | Grant or award | Common Stock | 175,250 | $1.41 | $247K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 83,689 | $1.39 | $116K | |
| Nicholas Grund - Officer | Grant or award | Common Stock | 204,000 | $0.00 | - | |
| Nicholas Grund - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| Steven Keith Burke - Officer | Grant or award | Common Stock | 204,000 | $0.00 | - | |
| Steven Keith Burke - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| Carolyn M. Rucci - Officer | Grant or award | Common Stock | 190,000 | $0.00 | - | |
| Carolyn M. Rucci - Officer | Grant or award | Stock Option (Right to buy) | 270,000 | $0.00 | - | |
| Richard C. Malabre - Officer | Grant or award | Common Stock | 79,000 | $0.00 | - | |
| Richard C. Malabre - Officer | Grant or award | Stock Option (Right to buy) | 119,000 | $0.00 | - | |
| Erik Ostrowski - Officer | Grant or award | Common Stock | 204,000 | $0.00 | - | |
| Erik Ostrowski - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| John P. Butler - Officer | Grant or award | Common Stock | 743,000 | $0.00 | - | |
| John P. Butler - Officer | Grant or award | Stock Option (Right to buy) | 1,115,000 | $0.00 | - | |
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 41,314 | $3.67 | $152K | |
| Leanne M. Zumwalt | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Adrian Adams | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Adrian Adams | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Akebia Therapeutics, Inc. (AKBA) had 8 insider filings in the last 90 days, with the most recent on 2026-08-10. The full record for AKBA runs to 26 Form 4 filings, the earliest from 2025-06-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AKBA were filed in the last 90 days. 1 purchase is on record for this company.
1 insider sale of AKBA was filed in the last 90 days, totaling $62K.
This page tracks AKBA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AKBA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
